ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biobased Chemicals

Almac moves on continuous flow, boosts peptides

by Rick Mullin
January 14, 2019 | APPEARED IN VOLUME 97, ISSUE 2

 

09702-buscon12-capturecxd.jpg
Credit: Almac
Almac has added peptide synthesis capabilities in Scotland.

Almac Sciences has completed an expansion of active pharmaceutical ingredient production in Craigavon, Northern Ireland, that adds continuous-flow manufacturing capabilities. The company also plans to implement continuous-flow manufacturing at its Arran Chemical facility in Athlone, Ireland. Meanwhile, Almac has added a second high-throughput peptide line at its Edinburgh, Scotland, facility, where it manufactures neoantigen-derived peptides for use in patient-specific cancer vaccines.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment